Respiratory Syncytial Virus (RSV): Maternal and Infant Protection Program

The RSV Maternal Vaccination Program: A single dose of maternal RSV vaccine Abrysvo® is available at any time of year, for women from 28 weeks of pregnancy to pass immunity to their infant., One dose is recommended in each pregnancy and is funded under the National Immunisation Program (NIP).

The seasonal RSV Infant Immunisation Program will be available from April to 30 September.

RSV Maternal Protection Program (Abrysvo)

RSV vaccines and RSV monoclonal antibody by age group or cohort

RSV vaccines and RSV monoclonal antibody by age group or cohort
Age group or cohort Abrysvo® 0.5ml (Pfizer) Arexvy® 0.5ml (GSK) BeyfortusTM (nirsevimab) 0.5/1.0ml (Sanofi)
Women from 28 weeks of pregnancy NIP funded Do Not Use Do Not Use
Infants and children ≤24 months Do Not Use Do Not Use Seasonal 2026 Annual Funded RSV Infant Protection Program - SA Schedule (PDF 176KB)
People 50-59 years with medical risk factors Do Not Use Available privately based on clinical decision Do Not Use
All people ≥60 years  Available privately based on clinical decision Available under the National Immunisation Program for adults 75 years and above and Aboriginal and Torres Strait Islander people aged 60 years and above Do Not Use

RSV Infant Protection Program (Beyfortus)

Clinical guidance

Dashboard

Department of Health, Disability and Ageing RSV information

Promotional resources